Effect of Monotherapy and Combination Therapy of Pantoprazole and Aprepitant in Gastric Esophageal Reflux Disease in Albino Rats
Table 3
Effect of pantoprazole and aprepitant as monotherapy and combination therapy on blood GSH, TBARS, SOD, and catalase in esophageal tissue.
S. number
Treatment (p.o.)
SOD (SOD/mg of protein)
TBARS (nM of MDA/mg of protein)
Catalase (nM of H2O2/min/mg of protein)
Blood GS H (mg%)
Group-I
Sham control (normal saline, 3 mL/kg)
5.32 ± 0.26
0.81 ± 0.08
24.49 ± 2.18
208.60 ± 3.83
Group-II
Toxic control (normal saline, 3 mL/kg)
0.89 ± 0.07***
7.50 ± 0.52***
7.02 ± 1.72***
74.20 ± 7.85***
Group-III
Pantoprazole (30 mg/kg)
3.16 ± 0.38***
3.06 ± 0.54***
18.01 ± 1.06***
141.00 ± 7.56***
Group-IV
Aprepitant (10 mg/kg)
3.72 ± 0.07***
2.10 ± 0.22***
22.00 ± 0.57
181.20 ± 10.04**
Group-V
Pantoprazole + aprepitant (30 mg/kg + 10 mg/kg)
4.50 ± 0.04***
1.06 ± 0.34
24.40 ± 0.97
194.20 ± 20.76
Each group contains six animals. Values are represented as mean ± SD. Statistical significance compared to toxic control using one-way ANOVA followed by Bonferroni test (*, **, and ***).
